BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30176891)

  • 41. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia.
    Takanashi M; Morimoto A; Yagi T; Kuriyama K; Kano G; Imamura T; Hibi S; Todo S; Imashuku S
    Haematologica; 2003 Nov; 88(11):1238-44. PubMed ID: 14607752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic Effect of CD20 Expression in Adult B-cell Acute Lymphoblastic Leukemia.
    Esteban RE; Christianne B; Alvaro A; Demichelis-Gómez R
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):361-367. PubMed ID: 29544762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.
    Meng X; Wang G; Liu P; Hou J; Jin Y; Yu Y; Bai J; Chen F; Sun W; Fu S
    Respirology; 2011 Nov; 16(8):1228-34. PubMed ID: 21883677
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of ABCB1 and ABCC1 gene induction on survival in locally advanced breast cancer.
    Atalay C; Demirkazik A; Gunduz U
    J Chemother; 2008 Dec; 20(6):734-9. PubMed ID: 19129072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy.
    Erdilyi DJ; Kámory E; Csókay B; Andrikovics H; Tordai A; Kiss C; Filni-Semsei A; Janszky I; Zalka A; Fekete G; Falus A; Kovács GT; Szalai C
    Pharmacogenomics J; 2008 Oct; 8(5):321-7. PubMed ID: 17938643
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
    N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.
    Hof J; Krentz S; van Schewick C; Körner G; Shalapour S; Rhein P; Karawajew L; Ludwig WD; Seeger K; Henze G; von Stackelberg A; Hagemeier C; Eckert C; Kirschner-Schwabe R
    J Clin Oncol; 2011 Aug; 29(23):3185-93. PubMed ID: 21747090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment.
    Piatopoulou D; Avgeris M; Marmarinos A; Xagorari M; Baka M; Doganis D; Kossiva L; Scorilas A; Gourgiotis D
    Br J Cancer; 2017 Sep; 117(6):801-812. PubMed ID: 28787435
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low CREBBP expression is associated with adverse long-term outcomes in paediatric acute lymphoblastic leukaemia.
    Gao C; Zhang RD; Liu SG; Zhao XX; Cui L; Yue ZX; Li WJ; Chen ZP; Li ZG; Rao Q; Wang M; Zheng HY; Wang JX
    Eur J Haematol; 2017 Aug; 99(2):150-159. PubMed ID: 28452416
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India.
    Priyadarshini R; Raj GM; Kayal S; Ramesh A; Shewade DG
    J Clin Pharm Ther; 2019 Apr; 44(2):188-196. PubMed ID: 30637776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. C-phycocyanin to overcome the multidrug resistance phenotype in human erythroleukemias with or without interaction with ABC transporters.
    Fernandes E Silva E; Figueira FS; Cañedo AD; Machado KS; Salgado MTSF; Silva TK; Wagner EF; Mattozo FH; Lima ÉA; Sales-Neto JM; Ferreira VU; Comitre AA; Mascarenhas SR; Kalil SJ; Votto APS
    Biomed Pharmacother; 2018 Oct; 106():532-542. PubMed ID: 29990841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Significance of MDR1, MRP1, GSTpi and GSTmu mRNA expression in acute lymphoblastic leukemia in Indian patients.
    Gurbuxani S; Singh Arya L; Raina V; Sazawal S; Khattar A; Magrath I; Marie J; Bhargava M
    Cancer Lett; 2001 Jun; 167(1):73-83. PubMed ID: 11323101
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
    Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.
    Suvannasankha A; Minderman H; O'Loughlin KL; Nakanishi T; Ford LA; Greco WR; Wetzler M; Ross DD; Baer MR
    Br J Haematol; 2004 Nov; 127(4):392-8. PubMed ID: 15521915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blast Percentage of Bone Marrow Aspirate on Day 14 of Induction Chemotherapy Predicts Adult Acute Lymphoblastic Leukemia Treatment Outcomes.
    Park HS; Kim DY; Choi EJ; Lee JH; Lee JH; Jeon M; Kang YA; Lee YS; Seol M; Cho YU; Jang S; Chi HS; Lee KH; Park CJ
    Acta Haematol; 2018; 139(4):220-227. PubMed ID: 29860259
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug resistance associated properties of blasts subpopulations with different CD34 expression in childhood acute lymphoblastic leukemia (ALL).
    Shman TV; Fedasenka UU; Savitski VP; Kustanovich AM; Aleinikova OV
    Exp Oncol; 2011 Sep; 33(3):145-9. PubMed ID: 21956467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.